BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 8151133)

  • 1. U937 cells can utilize plasminogen activator to regulate human interferon-gamma.
    Parmely MJ; Sterner KE; Gale A; Zhou WW
    J Interferon Res; 1993 Dec; 13(6):397-406. PubMed ID: 8151133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism by which U937 promonocytic cells inactivate human interferon-gamma.
    Duval-Jobe C; Leeson M; Rawitch A; Parmely MJ
    J Interferon Cytokine Res; 1995 Jun; 15(6):557-67. PubMed ID: 7553225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urokinase expression in mononuclear phagocytes: cytokine-specific modulation by interferon-gamma and tumor necrosis factor-alpha.
    Gyetko MR; Shollenberger SB; Sitrin RG
    J Leukoc Biol; 1992 Mar; 51(3):256-63. PubMed ID: 1311745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of plasminogen activation by human U937 promonocytic cells.
    Duval-Jobe C; Parmely MJ
    J Biol Chem; 1994 Aug; 269(33):21353-7. PubMed ID: 8063761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The THP-1 cell line is a urokinase-secreting mononuclear phagocyte with a novel defect in the production of plasminogen activator inhibitor-2.
    Gross TJ; Sitrin RG
    J Immunol; 1990 Mar; 144(5):1873-9. PubMed ID: 2307845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokine-specific regulation of urokinase receptor (CD87) expression by U937 mononuclear phagocytes.
    Sitrin RG; Todd RF; Mizukami IF; Gross TJ; Shollenberger SB; Gyetko MR
    Blood; 1994 Aug; 84(4):1268-75. PubMed ID: 8049441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasminogen activator inhibitor type-2 (PAI-2) in human keratinocytes regulates pericellular urokinase-type plasminogen activator.
    Reinartz J; Schaefer B; Bechtel MJ; Kramer MD
    Exp Cell Res; 1996 Feb; 223(1):91-101. PubMed ID: 8635500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parallel induction of fibrinolysis and receptors for plasminogen and urokinase by interferon gamma on U937 cells.
    Lu H; Mirshahi M; Krief P; Soria C; Soria J; Mishal Z; Bertrand O; Perrot JY; Li H; Picot C
    Biochem Biophys Res Commun; 1988 Aug; 155(1):418-22. PubMed ID: 2843185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation of cell surface-bound plasmin by cell-associated urokinase-type or secreted tissue-type plasminogen activator: a key event in melanoma cell invasiveness in vitro.
    Meissauer A; Kramer MD; Schirrmacher V; Brunner G
    Exp Cell Res; 1992 Apr; 199(2):179-90. PubMed ID: 1531956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The receptor for urokinase-type plasminogen activator of a human keratinocyte line (HaCaT).
    Reinartz J; Link J; Todd RF; Kramer MD
    Exp Cell Res; 1994 Oct; 214(2):486-98. PubMed ID: 7925643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells.
    Festuccia C; Dolo V; Guerra F; Violini S; Muzi P; Pavan A; Bologna M
    Clin Exp Metastasis; 1998 Aug; 16(6):513-28. PubMed ID: 9872599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis].
    Kobayashi H
    Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):623-32. PubMed ID: 8808830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endogenously produced urokinase amplifies tumor necrosis factor-alpha secretion by THP-1 mononuclear phagocytes.
    Sitrin RG; Shollenberger SB; Strieter RM; Gyetko MR
    J Leukoc Biol; 1996 Feb; 59(2):302-11. PubMed ID: 8604004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
    Holst-Hansen C; Johannessen B; Høyer-Hansen G; Rømer J; Ellis V; Brünner N
    Clin Exp Metastasis; 1996 May; 14(3):297-307. PubMed ID: 8674284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urokinase-type plasminogen activator stimulation of monocyte matrix metalloproteinase-1 production is mediated by plasmin-dependent signaling through annexin A2 and inhibited by inactive plasmin.
    Zhang Y; Zhou ZH; Bugge TH; Wahl LM
    J Immunol; 2007 Sep; 179(5):3297-304. PubMed ID: 17709546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokines induce urokinase-dependent adhesion of human myeloid cells. A regulatory role for plasminogen activator inhibitors.
    Waltz DA; Sailor LZ; Chapman HA
    J Clin Invest; 1993 Apr; 91(4):1541-52. PubMed ID: 8386190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-chain urokinase-type plasminogen activator does not possess measurable intrinsic amidolytic or plasminogen activator activities.
    Husain SS
    Biochemistry; 1991 Jun; 30(23):5797-805. PubMed ID: 1828371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urokinase plasminogen activator and plasmin efficiently convert hemofiltrate CC chemokine 1 into its active.
    Vakili J; Ständker L; Detheux M; Vassart G; Forssmann WG; Parmentier M
    J Immunol; 2001 Sep; 167(6):3406-13. PubMed ID: 11544332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urokinase plasminogen activator induces human smooth muscle cell migration and proliferation via distinct receptor-dependent and proteolysis-dependent mechanisms.
    Stepanova V; Mukhina S; Köhler E; Resink TJ; Erne P; Tkachuk VA
    Mol Cell Biochem; 1999 May; 195(1-2):199-206. PubMed ID: 10395084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receptor-mediated regulation of plasminogen activator function: plasminogen activation by two directly membrane-anchored forms of urokinase.
    Vines DJ; Lee SW; Dichek DA; Ellis V
    J Pept Sci; 2000 Sep; 6(9):432-9. PubMed ID: 11016879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.